Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human ribonucleotide reductase (RNR) is the rate-limiting enzyme responsible for the de novo production of deoxyribonucleotides (dNTPs), which are essential building blocks for DNA replication and repair [1][2]. The enzyme is a complex heterotetramer, and its activity is tightly controlled by the allosteric activity site (A-site) located on the large catalytic subunit, RRM1 [1][3]. This A-site acts as a master switch: the binding of ATP activates the enzyme to maintain dNTP production, while the binding of dATP induces a conformational change that promotes the formation of inactive α6β2 hexamers, effectively shutting down the enzyme [3][4]. This regulatory mechanism is a major target for several chemotherapeutic nucleoside analogs, such as clofarabine and fludarabine [5]. These drugs are intracellularly phosphorylated into triphosphate metabolites that bind to the A-site with high affinity, mimicking the inhibitory effect of dATP [4][6]. By locking the enzyme in an inactive state, these agents cause a profound depletion of dNTP pools, leading to replication fork collapse, DNA damage, and the induction of apoptosis in rapidly proliferating cancer cells [5][6]. Sources: [1] UniProt Consortium. UniProtKB - P23921 (RRM1_HUMAN). [2] Nordlund, P., & Reichard, P. (2006). Ribonucleotide Reductases. Annual Review of Biochemistry. [3] Fairman, J. W., et al. (2011). Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nature Structural & Molecular Biology. [4] Greene, B. L., et al. (2015). Ribonucleotide Reductases: Structure, Mechanism, and Drug Discovery. Drug Discovery Today. [5] Parker, W. B. (2009). Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chemical Reviews. [6] Bonate, P. L., et al. (2006). Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nature Reviews Drug Discovery.
Allosteric inhibition of enzyme activity via induction of inactive oligomerization (hexamerization) or competitive displacement of activating ATP.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleotide reductase catalytic subunit M1 (RRM1) allosteric activity site (RRM1 A-site).